FDA extends review of Capricor cell therapy; Pain drug startup to go public

Capricor's Duchenne muscular dystrophy cell therapy receives three-month FDA review extension

The FDA extended the review period for Capricor Therapeutics' experimental cell therapy deramiocel for Duchenne muscular dystrophy by three months after the company submitted new data with a refined indication.